|
Procter & Gamble (P&G) Health Limited has announced its financial results for the first quarter ended June 30, 2025. The company delivered a strong performance with sales of Rs. 333 crore, up 20% versus a year ago, owing to broad-based growth in domestic and exports business. Profit after tax (PAT) stood at Rs. 66 crore, versus Rs. 17 crore a year ago, due to strong sales growth and one-time impact of impairment in the base period.
Commenting on the performance, Milind Thatte, managing director, P&G Health India, said, "We are pleased with the continued momentum and strong start to the Financial Year 2025-26. These results are a reflection of our commitment towards addressing the evolving needs of our consumers and healthcare professionals, via superior brand building and go to market initiatives while improving supply chain capabilities.
He further added, “Our strategy, cantered on a focused portfolio of quality, trusted, and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution and value), constructive disruption and an agile accountable organization, is delivering balanced and sustainable growth results. We continue to drive engagement for our consumers and healthcare professionals alike, through innovation backed by science and meaningful interventions to make life a little better every day.”
Procter & Gamble Health Limited is one of India's largest vitamins, minerals, and supplements (VMS) companies manufacturing and marketing VMS products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion.
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur, Ariel, Gillette, Head & Shoulders, Olay, Oral-B, Pampers, Pantene, Tide, Vicks, and Whisper. P&G operates in approximately 70 countries worldwide.
|